Intervention Protocol

Inhaled mannitol for cystic fibrosis

  1. Judith Thornton1,*,
  2. Clare S Murray2,
  3. Mark Elkins3,
  4. Tiffany Dwyer3

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 4 AUG 2010

Assessed as up-to-date: 30 JUN 2010

DOI: 10.1002/14651858.CD008649


How to Cite

Thornton J, Murray CS, Elkins M, Dwyer T. Inhaled mannitol for cystic fibrosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008649. DOI: 10.1002/14651858.CD008649.

Author Information

  1. 1

    University of Manchester, Primary Care Research Group, Manchester, UK

  2. 2

    University of Manchester, Respiratory Group School of Translational Medicine, Manchester, UK

  3. 3

    Royal Prince Alfred Hospital, Department of Respiratory Medicine, Camperdown, Australia

*Judith Thornton, Primary Care Research Group, University of Manchester, 5th Floor, Williamson Building, Oxford Road, Manchester, M13 9PT, UK. judith.thornton@nice.org.uk. judith.thornton@manchester.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 4 AUG 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess whether inhaled dry powder mannitol is well tolerated and whether it improves the respiratory function, reduces respiratory exacerbations and improves the quality of life of people with CF.